

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



中國太平洋保險(集團)股份有限公司

CHINA PACIFIC INSURANCE (GROUP) CO., LTD.

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 02601)

Overseas Regulatory Announcement

This overseas regulatory announcement is made pursuant to Rule 13.09 and Rule 13.10B of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the “**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571 of the Laws of Hong Kong).

The announcement is attached hereof for information purpose only.

By Order of the Board
China Pacific Insurance (Group) Co., Ltd.
KONG Qingwei
Chairman

Shanghai, the PRC, 27 October 2018

As at the date of this announcement, the Executive Directors of the Company are Mr. KONG Qingwei and Mr. HE Qing; the Non-executive Directors of the Company are Mr. HUANG Dinan, Mr. WANG Tayu, Mr. KONG Xiangqing, Ms. SUN Xiaoning, Mr. WU Junhao and Mr. CHEN Xuanmin; and the Independent Non-executive Directors of the Company are Mr. BAI Wei, Mr. LEE Ka Sze, Carmelo, Mr. LAM Chi Kuen, Mr. ZHOU Zhonghui and Mr. GAO Shanwen.

* *Note: The appointment qualification of Mr. Huang Dinan is subject to approval by China Banking and Insurance Regulatory Commission.*

Summary of Quarterly Solvency Report

CPIC Allianz Health Insurance Co., Ltd.

3rd Quarter of 2018

Contents

I. BASIC INFORMATION	1
II. KEY INDICATORS	2
III. ACTUAL CAPITAL.....	2
IV. REQUIRED CAPITAL.....	2
V. COMPREHENSIVE RISK ASSESSMENT.....	3
VI. RISK MANAGEMENT STATUS	3
VII. LIQUIDITY RISK	4
VIII. REGULATORY MEASURES TAKEN AGAINST THE COMPANY	4

I. Basic information

(I) Registered address: 13th Floor, Building No. 1, 1229 Century Avenue, China
(Shanghai) Pilot Free Trade Zone, Shanghai, the PRC

(II) Legal representative: SUN Peijian

(III) Business scope and territories

1. Business scope:

Health insurance and accident insurance denominated in RMB and foreign currencies; health insurance commissioned by the government or supplementary to state medical insurance policies; reinsurance of the above said insurance ; health insurance-related agency and consulting business; insurance funds investment as approved by relevant laws and regulations; other business as approved by the CIRC.

2. Business territories:

Shanghai, Beijing, Guangdong Province, Sichuan Province

(IV) Ownership structure and shareholders:

1. Ownership structure

Equity category	Number of shares or contributed amounts (10K shares)	Percentage (%)
Domestic shares held by legal entities	130,986.70	77.05
Domestic shares held by natural persons		
Foreign shares	39,013.30	22.95
Others		
Total	170,000.00	100.00

2. Top 10 shareholders

Name of shareholders	Shares held or amounts contributed as at the end of the reporting period (10K shares)	Percentage of the shareholding (%)
1.China Pacific Insurance (Group) Co., Ltd.	130,986.70	77.05
2. Allianz Group	39,013.30	22.95

(V) Controlling shareholder or de facto controller:

China Pacific Insurance (Group) Co., Ltd.

(VI) Subsidiaries, joint or associate ventures:

Company name	Number of shares held (10k shares)	Percentage of the shareholding (%)
Shanghai Proton & Heavy Ion Hospital	10,000	20

(VII) Contacts for solvency information disclosure

1. Contact person: DING Liang
2. Telephone number: 021-33966101

II. Main indicators

Items	As at the end of this quarter/during this quarter	As at the end of last quarter/during last quarter
Core solvency margin ratio(%)	260	315
Core solvency margin (10K RMB)	68,060.01	78,124.24
Comprehensive solvency margin ratio(%)	260	315
Comprehensive solvency margin (10K RMB)	68,060.01	78,124.24
Latest comprehensive risks assessment	-	A
Premium income (10K RMB)	78,049.58	60,666.33
Net profit (10K RMB)	-3,988.62	-1,733.18
Net assets (10K RMB)	117,272.42	121,031.57

III. Actual capital

Items	As at the end of this quarter	As at the end of last quarter
Admitted assets (10K RMB)	369,357.42	323,290.53
Admitted liabilities (10K RMB)	258,730.48	208,907.60
Actual capital (10K RMB)	110,626.93	114,382.93
Tier 1 core capital (10K RMB)	110,626.93	114,382.93
Tier 2 core capital (10K RMB)	-	-
Tier 1 supplement capital (10K RMB)	-	-
Tier 2 supplement capital (10K RMB)	-	-

IV. Required capital

Items	As at the end of this quarter	As at the end of last quarter
Required capital (10K RMB)	42,566.92	36,258.69
Required capital for quantitative risks (10K RMB)	42,346.72	36,071.12
1) Required capital for insurance risk (10K RMB)	39,530.53	34,016.86
2) Required capital for market risk (10K RMB)	4,409.49	3,081.05
3) Required capital for credit risk (10K RMB)	3,770.62	3,117.14
Required capital for control risk (10K RMB)	220.20	187.57
Supplement capital (10K RMB)	-	-
1) Counter-cyclical supplement capital (10K RMB)	-	-

2) Supplement capital of D- SIIIs (10K RMB)	-	-
3) Supplement capital of G-SIIIs (10K RMB)	-	-
4) Other supplement capital (10K RMB)	-	-

V. Comprehensive risk assessment

Comprehensive risk assessment rating for Q2 2018: A; for Q1 2018: A.

VI. Risk management status

(I). The latest CBIRC solvency risk management assessment of the company

In 2017, the Company scored 78.96 points during the SARMRA risk assessment conducted by the CBIRC. To be specific, it received 14.07 points for risk management infrastructure and environment, 7.54 points for risk management objectives and tools, 8.02 points for insurance risk management, 8.00 points for market risk management, 8.00 points for credit risk management, 8.36 points for operational risk management, 8.08 points for strategic risk management, 8.22 points for reputation risk management, and 8.68 points for liquidity risk management.

(II). Measures taken to improve solvency risk management (if any) and the latest results in the reporting period.

As per Guidelines for Enterprise Risk Management of Life / Health Insurance Companies and Solvency Risk Management Regulation Standards (1-17) by CIRC, in the 3rd quarter, the Company's Management Committee submitted The 2018 Interim Report on Risk Management to the Board of Directors, with an all-around identification, analysis and assessment of the Company's solvency risk management, results of Comprehensive Risk Rating, and status of the 7 major risks. In view of the risk management status of the first half of the year, the Management Committee formulated plans of the Comprehensive Risk Rating, and initiatives on insurance, market and strategic risk management, with follow-up implementation. In the meantime, the Company continuously improved the IT support for risk management. In the reporting period, it completed the risk management IT system evaluation and needs analysis for 2019, developed and launched the visualized tools to further enhance IT application in risk management. As per solvency risk management rules and polices updated for 2018, all the corporate functions and branch offices performed

their duties in risk management with due diligence, with remedial actions proceeding as planned and the overall risk status under control.

VII. Liquidity risk

(I) Liquidity risk management indicators

1. Net cash flow

Items	During/as at the end of this quarter
Net cash flow (10K RMB)	-8, 596. 97

2. Comprehensive current ratio

Items	Within 3 months	Within one year	1-3 years	3-5 years	Above 5 years
Comprehensive current ratio	149	45	300	43, 916	-

3. Liquidity coverage ratio

Item	Stress scenario 1	Stress scenario 2
Liquidity coverage ratio (%)	2, 226	2, 176

(II) Liquidity risk analysis and countermeasures

The Company generated positive net cash flows under the baseline scenario and all stress scenarios, an indication of good liquidity. The net cash outflow in Q3 was mainly due to reinvestment of cash inflows as at the end of Q2, which led to net cash outflows from investment activities. The net cash flows for the reporting period were sufficient.

VIII. Regulatory measures taken against the Company

(I) Regulatory measures taken against the Company by CBIRC

CBIRC has not taken any regulatory measures against the Company.

(II) Corrective measures taken by the Company

None.